Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.British journal of haematology · 2019
   Guideline
2. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group.Annals of hematology · 2023
   Trial
3. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.Annals of hematology · 2018
   Trial
4. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.American journal of hematology · 2018
   Trial
5. Modern and multidisciplinary care in polycythemia vera.Annals of hematology · 2026
   Review
6. Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review.Journal of Zhejiang University. Science. B · 2023
   Review
7. Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens.Blood advances · 2023
   Article
8. Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus.Veterinary sciences · 2023
   Article
9. Enkurin: A novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens.bioRxiv : the preprint server for biology · 2023
   Article
10. Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting.Journal of cachexia, sarcopenia and muscle · 2022
    Observational
11. Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?Cancers · 2021
    Review
12. Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials.Current hematologic malignancy reports · 2021
    Review
13. Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation.Clinical case reports · 2021
    Article
14. Current Management of Chronic Neutrophilic Leukemia.Current treatment options in oncology · 2021
    Review
15. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.Frontiers in immunology · 2021
    Review
16. The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.Cancer medicine · 2020
    Article
17. Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.International journal of molecular sciences · 2020
    Review
18. Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms.Haematologica · 2020
    Article
19. Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.International journal of hematology · 2020
    Review
20. Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020
    Article

Corrections and comments

• Comment on
  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.2015
• Comment on
  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.2015

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as